Quantum Surgical receives €30 million loan from the European Investment Bank, with the support of InvestEU

·        The Montpellier (France)-based medical robotics company Quantum Surgical, has secured a financing of €30 million from the European Investment Bank (EIB).

·        This funding will support the global commercial development of Epione®, Quantum Surgical's platform dedicated to the curative and early treatment of inoperable tumors in the abdomen and lungs.

·        This investment benefits from the guarantee of the Invest EU program established by the European Commission.

This operation aims to accelerate the commercialization of the medicalrobot Epione, designed for minimally invasive treatment of abdominal and lung cancer.

After selling its first robot in the United States in December 2023 and the acquisition of Epione® by the Paoli-Calmettes Institute in Marseille in March 2024, the financing will accelerate the commercial development of the company. This is the second loan granted by the EIB to Quantum Surgical, following an initial financing in 2021 for the commercial launch of Epione®.

Epione® is a technology that enables interventional radiologists to perform safe and effective percutaneous tumorablations, a minimally invasive treatment where one or more needles are inserted through the skin to destroy the tumor.

Epione® is CE marked in Europe for abdomen and lung tumors, and FDA cleared for abdominal tumors. Epione® is available in France, at the Gustave Roussy Cancer Center in Villejuif, at the Hospices Civils de Lyon as well as at the Paoli-Calmettes Institute in Marseille, and in Miami, United States.

More than 4 million new cases of abdominal and lung cancers are diagnosed each year worldwide. Several hundred patients have already been treated worldwide using Quantum Surgical's medical platform.

"At Quantum Surgical, our goal is to provide patients with innovative and effective treatment on a global scale. We are delighted to receive support once again from the EIB. This demonstrates that our technology is destined for global adoption to revolutionize cancer treatment," says Bertin Nahum, CEO and co-founder of Quantum Surgical.

‍
"Already a partner of Quantum Surgical, the EIB is pleased to once again support the development of a surgical robot that has proven its worth in the medical field. This €30 million financing demonstrates Europe's commitment to supporting innovation and promising technologies in the healthcare sector, essential for improving the lives and well-being of patients on a much larger scale," stated Ambroise Fayolle, Vice President of the European Investment Bank.

‍